Sign in with Google
bearish
Biosimilar Battlefield Update: It's Getting Uglier
747 Views27 Nov 2018 16:29
A confluence of negative news is causing sharp declines (or trading suspensions) in the share prices of Samsung Biologics Co., (207940...
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 6-minute read)
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »- CATL H Share Listing: AH Discount Views
- Singapore: Lawrence Wong Boosted by Mild Improvement in PAP Vote Share
- ASX200 (AS51 INDEX) Outlook: Rallying Out of a Bear Market Amid Passive Flows And Sector Strength
- Last Week in Event SPACE: Toyota, Rio Tinto, Hainan Meilan, Fujitsu General
- (Mostly) Asia-Pac M&A: Ainsworth Game, Bright Smart, PointsBet, Dickson Concepts, Canvest, Shibaura
Top Unpaywalled Insights
More »Loading
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Celltrion Healthcare: Well, We Were Warned24 Feb 2019
- Biosimilar Battlefield: The Remsima/Inflectra Warning06 Feb 2019
- The Smartkarma Week That Was in JP/KR: Nissan, J-Retail, Tesla/Panny, SK Rights, Biosimilars, Trade02 Dec 2018
- Biosimilar Battlefield Update: It's Getting Uglier27 Nov 2018
- Samsung BioLogics Update22 Oct 2018
- Celltrion: Understanding Inflectra's U.S. Challenges21 Sep 2018
- Biosimilar Battlefield: An Update15 Feb 2018
x